Glioblastoma
Did you know:
The global Glioblastoma Multiforme (GBM) drugs market to reach nearly $1.8 billion by 2027, expanding at a CAGR of 12.8% during the forecast period, driven by rising geriatric population, growing incidence cases and rich clinical pipeline of new products.
A privately funded, clinical stage company that has developed and patented a lead therapeutic Carboxyamidotriazole Orotate (CTO)(Pravitinib(TM)) for the orphan indication glioblastoma (GBM) (fewer than 200,000 or 1 in 1500 persons are affected) and for other refractory targets.
Positioned to advance CTO into two Phase II/III registration-directed clinical trials as a potential new treatment for GBM in newly diagnosed and recurrent GBM patients.
